New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
13:43 EDTREGNRegeneron risk/reward favorable, says RBC Capital
RBC Capital views Regeneron's risk/reward as favorable at current levels given REGN727 data expected in 2013 and 2014.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
07:39 EDTREGNRegeneron announces EYLEA Injection recommended for approval in EU
Subscribe for More Information
January 21, 2015
10:16 EDTREGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 14, 2015
06:36 EDTREGNRegeneron price target raised to $474 from $390 at Citigroup
Subscribe for More Information
January 13, 2015
13:50 EDTREGNRegeneron sees FY14 EYLEA U.S. sales about $1.735B
Subscribe for More Information
12:40 EDTREGNAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use